C07D 239/95
With hetero atoms directly attached in positions 2 and 4
Official title: with hetero atoms directly attached in positions 2 and 4
C07D239/95 (With hetero atoms directly attached in positions 2 and 4) appears on 640 US grants and 546 published applications in this corpus.
Search patents in C07D- Granted patents
- 640
- Published applications
- 546
- Assignees
- 380
- Inventors
- 2,306
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 7 | 0 |
| 1978 | 11 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 5 | 0 |
| 1982 | 11 | 0 |
| 1983 | 7 | 0 |
| 1984 | 10 | 0 |
| 1985 | 8 | 0 |
| 1986 | 17 | 0 |
| 1987 | 13 | 0 |
| 1988 | 6 | 0 |
| 1989 | 13 | 0 |
| 1990 | 4 | 0 |
| 1991 | 6 | 0 |
| 1992 | 7 | 0 |
| 1993 | 14 | 0 |
| 1994 | 9 | 0 |
| 1995 | 8 | 0 |
| 1996 | 6 | 0 |
| 1997 | 7 | 0 |
| 1998 | 25 | 0 |
| 1999 | 23 | 0 |
| 2000 | 11 | 0 |
| 2001 | 21 | 6 |
| 2002 | 21 | 17 |
| 2003 | 18 | 16 |
| 2004 | 10 | 28 |
| 2005 | 12 | 33 |
| 2006 | 14 | 22 |
| 2007 | 13 | 31 |
| 2008 | 7 | 22 |
| 2009 | 16 | 24 |
| 2010 | 15 | 34 |
| 2011 | 22 | 30 |
| 2012 | 19 | 19 |
| 2013 | 25 | 24 |
| 2014 | 20 | 17 |
| 2015 | 16 | 17 |
| 2016 | 13 | 24 |
| 2017 | 20 | 14 |
| 2018 | 14 | 11 |
| 2019 | 13 | 18 |
| 2020 | 14 | 22 |
| 2021 | 13 | 14 |
| 2022 | 14 | 21 |
| 2023 | 10 | 30 |
| 2024 | 10 | 23 |
| 2025 | 9 | 19 |
| 2026 | 13 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Direct aromatic carbon-oxygen and carbon-hydrogen bond functionalization via organic photoredox catalyst8 Sep 2026US 12,729,169 B2The University of North Carolina at Chapel Hill
- Histone deacetylase inhibitors26 May 2026US 12,637,433 B2The University of Queensland
- Composition for use in the treatment of ApoL1-associated disease19 May 2026US 12,629,376 B2Vertex Pharmaceuticals Incorporated
- Broad spectrum anti-cancer compounds19 May 2026US 12,630,527 B2The Regents of the University of California
- Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient19 May 2026US 12,630,531 B2OMIC Smap Inc.
- Quinazolinone dione compounds and uses thereof3 Sep 2026US 2026/0258001 A1Edgewise Therapeutics, Inc.
- Benzopyrimidin-4(3h)-ones as pi3k inhibitors20 Aug 2026US 2026/0242398 A1OnKure, Inc.
- 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors30 Jul 2026US 2026/0217709 A1Ideaya Biosciences, Inc.
- Rna degraders and uses thereof16 Jul 2026US 2026/0199485 A1Arrakis Therapeutics, Inc.
- Novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative and method for preparing same16 Jul 2026US 2026/0200878 A1Kosin University Industry-Academy Cooperation
Most cited
By later US patents
- Compounds for inhibition of ceramide-mediated signal transduction117US 6,323,201 B1The Regents of the University of California · 2001
- Benzimidazoles for ischemic heart conditions96US 5,693,652 AEisai Co., Ltd. · 1997
- Compounds for inhibition of ceramide-mediated signal transduction96US 6,562,819 B2The Regents of the University of California · 2003
- Small molecule toll-like receptor (TLR) antagonists91US 7,410,975 B2Coley Pharmaceutical GmbH · 2008
- Fused heterocyclic compounds87US 7,615,552 B2Synta Pharmaceuticals Corp. · 2009